SUPPORT THIS INDEPENDENT JOURNALISM
The article you’re about to read is from our reporters doing their important work — investigating, researching, and writing their stories. We want to provide informative and inspirational stories that connect you to the people, issues and opportunities within our community. Journalism requires lots of resources. Today, our business model has been interrupted by the pandemic; the vast majority of our advertisers’ businesses have been impacted. That’s why The Capistrano Dispatch is now turning to you for financial support. Learn more about our new Insider’s program here. Thank you.
Quest Diagnostics will attempt to identify new mutations of SARS-CoV-2—which causes COVID-19—as part of an agreement with the Centers for Disease Control and Prevention, the medical information company announced in a news release.
The studies will be done at the company’s lab in San Juan Capistrano, using viral genomes of random de-identified samples.
“Public and private collaboration is essential to mobilizing an effective response to COVID-19,” Jay G. Wohlgemuth, M.D., Senior Vice President and Chief Medical Officer, said in the news release. “Quest has the expertise in genomics and infectious diseases, as well as extensive COVID-19 testing data and access to patient samples.”
The sequencing results will reportedly be combined with the results of other data provided to the CDC as part of a CDC survey, which intends to identify changes in transmission and new virus variants.